Physician profile
George Dowell
NPI 1750491130
$3,403.98
in general payments reported to CMS, 2019-2025
28 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $318 · 2021: $162 · 2022: $77.26 · 2023: $552 · 2024: $408 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $499.13 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $406.01 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $338.98 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $330.17 | 2019-2025 | Rexulti |
| Abbvie INC. | $264.07 | 2021-2025 | Vraylar |
| Allergan, INC. | $243.69 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $140.54 | 2019-2025 | Ingrezza |
| Corium, LLC | $137.40 | 2023-2025 | Azstarys |
| Alkermes, INC. | $135.90 | 2019-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $112.38 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $95.47 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $82.56 | 2019-2024 | Fanapt |
| Adlon Therapeutics L.P. | $64.87 | 2019-2020 | |
| Almatica Pharma LLC | $62.16 | 2021-2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $61.52 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $53.94 | 2019-2024 | |
| Shire North American Group INC | $53.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.65 | 2020-2023 | Trintellix |
| Bausch Health US, LLC | $51.24 | 2019 | |
| Neos Therapeutics, Lp | $51.19 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.00 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $29.97 | 2019 | |
| Tris Pharma INC | $17.32 | 2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $15.97 | 2019 | |
| Amgen INC. | $15.65 | 2019 | |
| Indivior INC. | $15.63 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $12.89 | 2019 | |
| Novo Nordisk INC | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.